

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-994

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-994

Alcon, Inc.
c/o Alcon Research, Ltd.
Attention: Angela C. Kothe, O.D., Ph.D.
Associate Director, Regulatory Affairs
Mail Code R7-18
6201 South Freeway
Fort Worth, Texas 76134-2099

Dear Dr. Kothe:

Please refer to your new drug application (NDA) dated November 18, 2005, received November 21, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Travatan Z (travoprost ophthalmic solution) 0.004%.

We acknowledge receipt of your submissions dated November 18, and December 7 and 14, 2005, and January 10, March 15, July 25, August 15, and September 1, 6, 15, and 18, 2006.

This new drug application provides for the use of Travatan Z for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to other intraocular pressure lowering medications.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed draft labeling submitted on September 15, 2006. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug. Please submit the content of the labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical to the enclosed draft labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for posting on the DailyMed website.

NDA 21-994

Page 2

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to and this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Project Manager, at (301) 796-0791.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective and
Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure

Appears This Way
On Original

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth
9/21/2006 03:22:29 PM

Appears This Way
On Original